Crispr Therapeutics remains a top pick for 2019 at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff says Crispr Therapeutics remains a top pick for 2019 following the company’s Q1 results. The company has a cash position of $456M its Phase I/II study of CTX001 in transfusion-dependent beta thalassemia is “on-going,” which suggests the first patient has successfully engrafted representing a “significant milestone,” Tenthoff tells investors in a research note. He expects “first-in-man data” from both Phase I/II studies later this year to “serve as a major driver” and reiterates an Overweight rating on the stock with a $75 price target.

https://thefly.com/landingPageNews.php?id=2899469